Judit Axmann
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis.
Journal: Frontiers in medicine
Published: March 15, 2022
Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use.
Journal: Advances in therapy
Published: October 01, 2021
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Journal: The Lancet. Respiratory medicine
Published: July 16, 2019
Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation.
Journal: Annals of the American Thoracic Society
Published: April 06, 2019
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial.
Journal: BMJ open respiratory research
Published: May 09, 2018
Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views.
Journal: Respiration; international review of thoracic diseases
Published: February 12, 2018
Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.
Journal: BMC pulmonary medicine
Published: June 29, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026